samplethymic immunity
98%+ · 5mg · Lyophilized · MW: 3108.3
Bulk discount
3+ pcs
€75.05
−5%
5+ pcs
€71.10
−10%
10+ pcs
€67.15
−15%
Discount is applied automatically at checkout.
Enter your email and we'll notify you when it's back:
Free shipping over €49
This product is sold strictly for in lab conditions (in vitro) research purposes. Not approved for human consumption.
Verified above 98%
98%+ verified — most batches reach 99%+
Included
Independent analysis from accredited laboratories
EU Shipping
3-7 days across the EU (Bulgaria — 1-2 days)
Secure Payment
Cash on delivery
Thymosin Alpha 1
Synthetic Thymic Hormone | Immune System Modulation
In short
28-amino acid peptide studied in immunological models for modulation of T-cell response and antiviral activity.
Best sellers
Related resources
Ready-to-use starter kit
Thymosin Alpha 1 is a synthetic peptide consisting of 28 amino acids, structurally identical to a naturally occurring hormone found in the thymus gland. At the molecular level, it interacts with the immune system by activating specific cellular pathways (TLRs) and stimulating the maturation of T-cells and the activity of natural killer (NK) cells. Scientists are investigating this molecule in laboratory (in vitro) and animal models to analyze its capacity for modulating the immune response. Although the same active ingredient is present in some approved medical products (such as Zadaxin), the peptide offered here is intended exclusively for scientific research and is not a medication for human use.
Research reagent for laboratory use only. Not a medicine. For medical questions, consult a physician.
Scientific review
Written by
Калина Тодорова
Magister Pharmaciae, MSc Pharmacy
Reviewed by
Борис Маринов
MSc Biochemistry & Molecular Biology
Reviewed on
Thymosin Alpha 1 (Ta1/Thymalfasin/Zadaxin) is a synthetic 28-amino acid peptide identical to the naturally occurring thymic hormone. With over 11,000 patients studied across 30+ clinical trials, it holds FDA orphan drug designations for four conditions and is approved in 35+ countries worldwide. Ta1 demonstrates exceptional safety with less than 1% serious adverse events while providing comprehensive immune system modulation.
Goldstein thymosin series (28 aa) Registered in 35+ countries (Zadaxin) TLR9 dendritic cell activation CD4+ T-cell restoration (Camerini 2020)
Injectable Ta1 provides optimal bioavailability (90-95%) with rapid Tmax of 2 hours. Activates multiple TLR pathways, enhances T-cell maturation, stimulates NK cells, and modulates dendritic cell function through systemic circulation.
FDA orphan drug designation for DiGeorge syndrome with documented restoration of T-cell function and immune competence in clinical trials.
Enhances immunogenicity in elderly and hemodialysis patients with improved antibody responses to H1N1 and COVID-19 vaccines.
Restores CD4+ T-cell counts and reduces opportunistic infections in HIV patients with sustained immunological improvement.
Dosing
The typical regimens you'll see in the published research - for reference when planning in vitro or in vivo experiments. Not medical advice.
Disclaimer
These are regimens discussed in the research literature, not medical advice. Consult a healthcare provider before use.
Timing
Any time, consistent schedule
[Calculator]
Change water and dose · results update in real time
from product
Visual indicator
Pull to mark 10
10marks
Standard insulin syringe 1 ml (100 marks)
Concentration
2.50mg/ml
Dose volume
0.100ml
U-100 units
10units
Doses per vial
20doses
Recommended needle
29G–30G / 1 ml insulin
Small volume — draw slowly; 30G works for finer precision
Cycle planner: vials for 12 weeks, cost, schedule
Opens full calculator
Results are reference values - for in vitro work. Verify against the published literature for the specific peptide.
[Step by step]
6 steps from a sealed vial to the injection. Plain language.
Peptide vial (5 mg), bacteriostatic water vial, 1 larger syringe (3-5 ml) for drawing water and 1 insulin (1 ml) for doses. Alcohol swabs for sanitizing the caps.
Wash your hands before starting.
Wipe the rubber cap of the water vial with an alcohol swab. Insert the needle, invert the vial and draw exactly 2 ml. Get the exact volume from the calculator.
Larger syringe = smaller error in volume.
Wipe the peptide vial cap. Tilt the vial 45° and release the water SLOWLY down the inner wall. Peptides are fragile — a direct stream onto the powder denatures them.
SLOWLY · DOWN THE WALL · NOT ONTO THE POWDER.
Hold the vial between both palms and swirl slowly. DO NOT shake or flip sharply — peptides break down under mechanical stress.
DON'T SHAKE. Like tea — not like a cocktail.
The powder should fully dissolve. The solution is clear, no visible particles. If cloudy or with sediment — discard (wrong water or bad batch).
Clear = OK. Cloudy = discard.
With the insulin syringe draw the exact marks from the calculator. Swab the skin (abdomen 5 cm around the navel, thigh, or buttock), pinch a fold, insert at 45-90° and inject slowly.
Rotate sites every injection to avoid lipohypertrophy.
Schedule
Any time, consistent schedule
Clean work area and hands thoroughly
Add 1.0 mL sterile water slowly to lyophilized powder
Inject water slowly down vial side (not directly onto powder)
Gently swirl until completely dissolved (never shake)
Final concentration: 1.6 mg/mL
Use promptly or refrigerate at 2-8°C for up to 7 days
Exceptional safety profile with <1% serious adverse events across 11,000+ patients
Most common side effect: mild injection site reactions (<10%)
Contraindicated in organ transplant recipients (risk of graft rejection)
Monitor for hypersensitivity reactions with first dose
Not recommended during pregnancy or breastfeeding
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Comprehensive Safety Evaluation Study (2024)
Multiple species | Up to 16mg/kg | 6-12 months | Exceptional safety profile
Comprehensive review across 11,000+ patients in 30+ clinical trials showing <1% serious adverse events, establishing excellent long-term safety profile for potential clinical applications.
View the studyPost-Acute COVID-19 Immune Restoration Study
Human | 1.6mg SC twice weekly | 12 weeks | Immune homeostasis restoration
Study demonstrating Ta1's ability to restore immune homeostasis in lymphocytes during post-acute sequelae of SARS-CoV-2 infection with normalized T-cell populations and reduced inflammatory markers.
View the studyCytokine Storm Mitigation in COVID-19 Patients
Human | 1.6mg SC daily | 7 days | 40-60% cytokine reduction
Clinical study showing significant reduction in pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 while maintaining balanced immune responses in coronavirus disease patients.
View the studyCOVID-19 Treatment Efficacy Study (2020)
Human | 1.6mg SC twice daily | 14 days | 30% vs 11% mortality reduction
Randomized trial demonstrating significant mortality reduction in severe COVID-19 patients through restoration of lymphocytopenia and reversal of exhausted T cells. Primary endpoint showed dramatic improvement in survival rates.
View the studyTESTS Phase 3 Sepsis Trial (NCT02867267)
Human | 1.6mg SC twice daily | 28 days | Mixed mortality outcomes
Largest randomized controlled trial with 1,106 sepsis patients evaluating mortality benefit. While overall results were negative, subgroup analysis suggested potential benefits in specific populations.
View the studyThymalfasin COVID-19 Pilot Trial (NCT04487444)
Human | 1.6mg SC daily | 5 days | Improved lymphocyte recovery
Pilot study in 49 hospitalized COVID-19 patients with hypoxemia and lymphocytopenia showing enhanced immune recovery but mixed clinical outcomes. Completed recruitment with published safety data.
View the study
for longevity
for sexual health
No reviews yet. Be the first.
Share your experience with this peptide. We publish after a short moderation.
